Vækstaktier

DanCann Pharma indgik i foråret en distributionsaftale med den canadiske cannabinoid virksomhed Tetra Bio-Pharma omhandlende produkterne Reduvo, Adversa og Qixleef i Danmark, Sverige, Norge Tyskland og Finland.

Tetra Bio-Pharma er efter succesfulde fase 1 studier påbegyndt deres fase 2 studier for Qixleef, som er et middel mod smerter ifm. kræftbehandling. Qixleef indeholder cannabinoiderne THC og CBD, som lever op til de amerikanske reguleringer indenfor området.

I Tetra Bio-Pharmas indledende fase 2 studier for Qixleef har virksomheden præsenteret positive kliniske data.

Dr. Guy Chamberland, CEO og CRO for Tetra Bio-Pharma udtaler i denne forbindelse:

A safe and efficient therapeutic alternative that allows the reduction of opioids is critical now more than ever to support patients in their journey against pain. Preliminary data from both REBORN©1 and PLENITUDE© confirm the safety and pharmacodynamic profile of QIXLEEF™ reported in the phase I trials. The pharmacokinetic profile of QIXLEEF™ is well indicated to help manage short episodes of pain such as breakthrough pain and will offer patients and physicians a viable, safer, and non-opioid option for pain management.